CARL vs IDXX · rev $50.5M vs P/E 40, rev $2.36B
Carlsmed, Inc. Common Stock (CARL) versus IDEXX Laboratories Inc (IDXX) — a side-by-side from cached financials, not a winner call.
Carlsmed, Inc. Common Stock (CARL) is a health information services company listed on NASDAQ.
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
Latest reported CARL revenue for 2025-12-31 was $50.5M. Net income was -$29.6M. Revenue was up 85.9% from 2024-12-31 to 2025-12-31. CARL currently screens at market cap $299.7M.
Latest reported IDXX revenue for 2026-06-30 was $2.36B. Net income was $616.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
CARL currently screens at market cap $299.7M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
Not investment advice. Open the CARL and IDXX stock pages for the full models.
Not investment advice.